The Swiss pharmaceutical company Roche takes over the American gene therapist Spark Therapeutics. The deal has a value of 4.8 billion dollars, as was announced on Monday. Specifically, there is a bid of $ 114.50 per share on the table. The board of Spark is behind the deal, which is likely to be completed in the second quarter. Spark develops and delivers gene therapies, and has a therapy in research for the treatment of haemophilia A. Spark continues to operate as an independent company within the Roche group. The French pharmaceutical company Ipsen is also taking over the Canadian Clementia Pharmaceuticals for 1.3 billion dollars. The deal is being met as a two-stage rocket. Initially, the purchase price is $ 25 per share in cash. Another $ 6 per share can be added if a treatment for a rare bone disorder from Clementia is approved by the US regulator FDA. The board of Clementia supports the bid, which is expected to be completed in the second quarter of the year.